A proof-of-concept study has identified drugs that may benefit some hospitalized patients. COVID-19 (new coronavirus infection) pneumonia.
A proof-of-concept study led by the University of Birmingham and the University of Birmingham Hospital The Birmingham NHS Foundation Trust has identified drugs that may benefit some patients admitted with COVID-19 pneumonia.
In the CATALYST trial, UK-based biopharmacy company Izana Bioscience’s namilumab (IZN-101) is a potential treatment to treat patients who have been hospitalized for COVID-19 pneumonia and are receiving “normal” treatment. Tested as a law. Blood, a marker of inflammation known as C-reactive protein (CRP). Inflammation in the body increases CRP levels, which have been shown to be potential early markers for predicting the risk of COVID-19 severity.
Namilumab, an antibody already in late-stage trials to treat rheumatoid arthritis, targets “cytokines” that are naturally secreted by immune cells in the body, but at uncontrolled levels, it is seen in excess. In COVID-19 patients, which is considered to be a major driver of dangerous lung inflammation.
Trial conducted jointly with Oxford University COVID-19 pneumonia, funded by the Medical Research Council, conducted between June 2020 and February 2021 and treated in nine NHS hospital wards or intensive care units (ICUs) throughout the UK. Patients over 16 years of age were involved.
A study published on December 16, 2021 Lancet Respiratory medicine, 54 patients receiving “conventional care” (steroids and oxygen or ventilation depending on the severity of the disease) and 57 patients receiving conventional care and a single intravenous dose of 150 mg namilumab. I was involved.
Similar to COVID-19 pneumonia, all study participants had CRP levels above 40 mg / l. The researchers compared the probability that patients’ CRP levels would decrease. Compared to regular care alone, researchers found that patients receiving namilumab had a 97% chance of lowering CRP over time when compared to regular care alone. ..
Patients were monitored and a 28-day study also showed that patients who received namilumab had fewer deaths and more discharges from the hospital or ICU than those who received regular care alone. ..
By day 28, 78% (43) of patients receiving namilumab were discharged from the hospital or ICU, while 61% (33) of patients receiving conventional treatment were discharged. By day 28, 11% (6) were still hospitalized in the namilumab group, compared to 20% (11) in the regular care group. Of the patients in the namilumab group, 11% (6) died, compared to 19% (10) who died in the regular care group by day 28.
The team calculated the difference between the two cohorts of overall probability of being discharged from the ICU or ward in 28 days. Of the patients in the ward, the probability of discharge on day 28 was 64% in the regular care cohort, compared to 77% in the Namilmab cohort. Of the ICU patients, the probability of discharge on day 28 was 47% in the regular care group and 66% in the Namilmab cohort.
Dr. Ben Fisher, Co-Principal Investigator for CATALYST Exam University of BirminghamThe Rheumatologist, a consultant at the Institute for Inflammation and Aging, and the University Hospital Birmingham NHS Foundation Trust (UHB), said: However, our sample size is too small for a definitive assessment of clinical outcomes, which requires further study and a better understanding of the population that may benefit most. .. Our results may not be generalized to inpatients with no evidence of pneumonia or elevated CRP, or patients who do not require hospitalization. Therefore, it is important that namilumab is prioritized for further COVID-19 studies in a much larger national phase III clinical trial. ”
Dr. Someit Sidhu, co-founder of Izana Bioscience, said: “We are proud to be able to support the CATALYST trial led by an experienced team at the University of Birmingham and UHB, Europe’s largest integrated critical care center.” Namilumab is found in patients with severe COVID-19 infections. We believe that we can play an important role in controlling inflammation and work with regulators and partners around the world to develop this potential treatment for patients with COVID-19. This is a particularly important moment for me, and through the work of a team at the University of Birmingham Hospital, a hospital that trained as a junior doctor before finding Izana, to this pandemic. We support the global response of. “
The CATALYST team has also tested a second drug called infliximab (CT-P13), which is currently used to treat inflammatory conditions. They had 35 patients with COVID-19 pneumonia and the same patients with CRP levels above 40 mg / l receiving “normal care” receiving regular care and a single intravenous dose of 5 mg / kg infliximab. Compared with the patient. However, in this study, infliximab was less effective than regular care, with a only 15% chance of lowering CRP.
Dr. Fisher said: .. “
Reference: “Namilmab or infliximab compared to standard treatment in COVID-19 (CATALYST) inpatients: randomized, multicenter, multigroup, multistage, open-label, indication, phase 2, proof-of-concept study” Benjamin A Fisher, MD[Res]Professor Tony Venice, Ph.D.; Daniel Slade, Master’s Program; Charlotte Gaskell, MSc; Matthew Roland, DPhil; Professor Tony Whitehouse, Maryland; James Scriven, PhD; Dhruv Parekh, PhD; Madhu S Balasubramaniam, MBBS Professor Graham Cook, DPhil; Nick Morley, MBBS; Zoe Gabriel, MBBS; Matthew P Wise, DPhil; Professor Joanna Porter, Ph.D.; Professor Helen McShane, Ph.D.; Professor Ling-Pei Ho, DPhil; Philip N. Professor Newsum, Ph.D.; Dr. Annalow; Rowena Sharpe, PhD; Professor David R. Ticket, DM; Professor Julianbion, MD; Professor Simon Gates, Ph.D.; December 16, 2021, on behalf of CATALYST investigators. Professor Duncan Richards (DM) and Professor Pamela Kerns (PhD). Lancet Respiratory Medicine..
DOI: 10.1016 / S2213-2600 (21) 00460-4
Designed by the Inflammation-Advanced Cell Therapy Trial Team (I-ACT) of the University of Birmingham Cancer Research UK Clinical Trials Unit, CATALYST operates in close collaboration with UHB and the Birmingham National Institute of Health Biomedical Research Center (NIHR). It has been. Provided in close cooperation with BRC) and NIHRBRC in Oxford. Imperial College London And University College London.
Rheumatoid arthritis drugs can treat patients hospitalized for COVID-19 pneumonia more effectively
https://scitechdaily.com/drug-could-more-effectivelrheumatoid-arthritis-drug-could-more-effectively-treat-patients-hospitalized-with-covid-19-pneumoniay-treat-patients-hospitalised-with-covid-19-pneumonia-early-stage-research/ Rheumatoid arthritis drugs can treat patients hospitalized for COVID-19 pneumonia more effectively